Cerevel (CERE) - Kapitalizatsiyaning foydaga nisbati
Cerevel Therapeutics (CERE) kompaniyasining neyromeditsina sohasidagi ishlanmalari patent huquqi va reagentlar ta'minotiga ta'sir ko'rsatuvchi global mojarolar tufayli murakkablashgan. GURU.Markets platformasidagi ushbu narxlar grafigi ko'rsatkichni -17.80 darajasida qayd etib, buni tasdiqlaydi. Cerevel Therapeutics (CERE) xarajatlarni minimallashtirish uchun dori vositalarini sintez qilishda tashqi pudratchilarga tayanadi, shu bilan birga, kuchli sog'liqni saqlash gigantining qo'llab-quvvatlashi moliyaviy barqarorlikni va ilmiy tadqiqotlarning uzluksiz rivojlanishini ta'minladi.
Cerevel Therapeutics Inc (CERE) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning xususiy kapitalga nisbati Cerevel Therapeutics|CERE - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati cerevel.com|CERE - Kompaniya qarzlari|Qarzning balans kapitallashuviga nisbati Cerevel Corp|CERE - Kompaniyaning uzoq muddatli majburiyatlari|Kompaniyaning qisqa muddatli kredit va qarzlari Cerevel Therapeutics|Oraliq likvidlik koeffitsiyenti cerevel.com
- foyda va baholash multiplikatorlari ko'rsatkichlari:
CERE - Sof foyda|Kutilayotgan sof daromad Cerevel Therapeutics|CERE - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Cerevel Corp|CERE - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Cerevel Therapeutics Inc|CERE - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) Cerevel Therapeutics|CERE - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik dinamikasi cerevel.com|CERE - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi Cerevel Therapeutics
- kompaniyaning sotuvlari va tushumi statistikasi:
Kompaniyaning har tomonlama tahlili:Cerevel
Cerevel Therapeutics markaziy nerv tizimining og'ir buzilishlari uchun innovatsion terapiyalarni ishlab chiqishga ixtisoslashgan. Kompaniyaning foydaga nisbatan narx koeffitsiyentini tahlil qilib, investor -17.80 joriy qiymatini ko'radi. Ushbu koeffitsient shakllantirilgan sof foyda asosida kapitalizatsiyaning qoplash muddatini belgilaydi. Metrikaning dinamikasi tebranishlar davrida biotexnologik aktivlarning bozor qiymati qayta baholanishini baholash imkonini beradi. Bu emitentning sanoat etaloniga nisbatan xavfsizlik zaxirasini aniqlashga yordam beradi.
Raqobatdosh kompaniyalar
Narxning foydaga nisbati BIIB|P/E multiplikatori NBIX|Regencell (RGC) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narxning foydaga nisbati axsome.com AXSM|P/E multiplikatori ACADIA Pharmaceuticals ACAD|XENE - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Narxning foydaga nisbati|CPRX (Catalyst Pharmaceuticals) - Narxning foydaga nisbati|DNLI (denalitherapeutics.com) - P/E multiplikatori|Narx-foyda multiplikatori HRMY (Harmony Biosciences Holdings, Inc.)|P/E multiplikatori BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Kapitalizatsiyaning sof foydaga nisbati|anavex.com - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati CBLL (CeriBell, Inc.)|PRTA: P/E multiplikatori|Narx-foyda multiplikatori ALEC|ANNX (Annexon Biosciences Inc.) - P/E multiplikatori|omeros.com - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati Neurogene (NGNE)|Biznesning o‘zini qoplash muddati AC Immune SA|P/E multiplikatori VYGR (voyagertherapeutics.com)|P/E multiplikatori Neumora NMRA|Scilex Holding - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Tevogen Bio Inc.|Alpha Cognition (ACOG) - Narxning foydaga nisbati|cogrx.com (CGTX) - P/E multiplikatori|Narxning foydaga nisbati Inhibikase Therapeutics|Cassava (SAVA) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Assertio Therapeutics (ASRT)|Biznesning o‘zini qoplash muddati Coya|Vistagen - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati OVID|Acumen Pharmaceuticals Inc. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati CervoMed Inc|ATHE: P/E multiplikatori|Narx-foyda koeffitsiyenti Clene Nanomedicine|Narxning foydaga nisbati PepGen Corp|Jupiter Neurosciences (JUNS) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Relmada Therapeutics, Inc. (RLMD)|ANVS - Kapitalizatsiyaning foydaga nisbati|gracetx.com - Narx-foyda koeffitsiyenti|AIFF: Narx-foyda multiplikatori|Klotho Neurosciences - P/E multiplikatori|NRSN (NeuroSense Therapeutics Ltd.) - Narx-foyda multiplikatori|Reviva Pharmaceuticals (RVPH) - Narxning foydaga nisbati|MTVA (MetaVia Inc.) - Narxning foydaga nisbati|Narxning foydaga nisbati NeurAxis, Inc|Narxning foydaga nisbati HSDT|P/E multiplikatori PASG|Biznesning o‘zini qoplash muddati Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Narx-foyda koeffitsiyenti|P/E multiplikatori Athira ATHA|Addex Therapeutics - P/E multiplikatori|ALZN - P/E multiplikatori|Cyclerion (CYCN) - Narxning foydaga nisbati|Protagenic (PTIX) - P/E multiplikatori|Narxning foydaga nisbati Pasithea|Narx-foyda multiplikatori CRGT (Cortigent)|Narxning foydaga nisbati Avenue Therapeutics (ATXI)|BCLI - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori CARA (Cara Therapeutics Inc)|CHRO - Narx-foyda koeffitsiyenti|ELYM: Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Narxning foydaga nisbati|Marinus - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati NKGen Biotech Inc|NRBO: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti SAGE (Sage Therapeutics, Inc.)|Biznesning o‘zini qoplash muddati Neurotrope|Narxning foydaga nisbati Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Kapitalizatsiyaning foydaga nisbati|WENA: Narx-foyda koeffitsiyenti
